A new Series of –pyrazole-[1,2,4]triazolo[4,3-a]pyrimidine hybrids (4a-f) was synthesized via an efficient one-pot, three-component strategy involving chalcone intermediates and 2-amino-1,2,4-triazole. The structures of the synthesized compounds were confirmed by FTIR, 1H NMR, 13C NMR, HRMS and elemental analysis. The anticancer potential of these derivative was evaluated against the MCF-7 breast cancer cell line using the MTT assay, where compounds 4b (IC50=28.41µg/mL) and 4d (IC50=25.26 µg/mL) exhibited significant cytotoxiciy comparable to cisplatin. Overall, these results suggest that pyazole-triazoloprimidine scaffolds, particularly 4b and 4d, represent prosing anticancer candidates with potential diagnostic applications.